Molteni

Molteni Farmaceutici SpA is a leading specialist in the market of opioid drugs, a company that has always been responsible and committed to the research and implementation of therapeutic solutions for the treatment of pain and addictions in defense of quality of life and the right to adequate therapy of patients.

Molteni Farmaceutici is one of the centers of excellence of European pharmaceutical production and has over time acquired its distinctive competitive know-how in the development, production and marketing of opioid drugs.

A solid past behind, the awareness of its value and the ability to look with determination to the future make Molteni Farmaceutici an excellence, Italian, Tuscan and Florentine, in the increasingly global market of the drug. For over a century.

Molteni today and tomorrow

The new Molteni Farmaceutici plant in Florence is a modern structure, equipped with innovative technical and scientific technologies and instruments, at the cutting edge of quality and production volumes, which has highly qualified personnel and has its strong point in the consolidated technology of production of injectable aseptic solutions, used in several company departments organized for production capacity and pharmaceutical form.

The activation in 2014 of a new production department with controlled contamination of nasal spray narcotic solutions, which today is a European production platform for the production of a drug for the treatment of pain.

Starting from the 2000s Molteni Farmaceutici intensifies its research activity making use of its own internal operating unit and the collaboration of numerous university centers. In particular, in the therapeutic area of ​​addictions, a scouting process is active for new molecules in the early stage phase and new indications, concentrations and formulations are being developed and registered to ensure an always better compliance and adherence to the treatment of drugs. narcotics. In the pain treatment area, the commitment is aimed at consolidating its position in the specialist sector through a portfolio management strategy that also involves the acquisition of international licenses for innovative products.

In 2006, Molteni Therapeutics was founded, which, through the development of its own platform of innovative photosensitizing molecules, concludes in 2015 the first European authorization of a medical device for the treatment of infected diabetic foot ulcers with photo-dynamic therapy.

A modern structure and organization

At a structural and organizational level Molteni Farmaceutici has recently re-engineered its business processes, obtaining in April 2017 the renewal of the ISO 9001 certification new 2015 standard; is in the process of imminent transition to the SAP ERP system; in September 2017 it completed its management and control model pursuant to Legislative Decree 231; and will fill in its 2017 consolidated financial statements according to the IAS / IFRS international accounting standards.